In an interview with PharmaShots, Chris Arendt, Head of the Oncology Therapeutic Area Unit at Takeda shared his views on the new data of Alunbrig in the P-III ALTA-1L study for the Treatment of ALK+ mNSCLC
Shots:
The P-III ALTA-1L study evaluates Alunbrig vs Crizotinib in patients with ALK+ mNSCLC who have not received prior treatment with an ALK inhibitor
The results showed…
